drugset / Trial / NCT00619892

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

NCT00619892

Phase 4 Completed 26 enrolled Indiana University AstraZeneca · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to test the hypothesis that a SSRI plus quetiapine SR (Seroquel SR) will result in superior early (first 1-3 weeks of treatment) stabilization of panic symptoms in SSRI-resistant, comorbid Panic Disorder patients versus a SSRI plus placebo.

Timeline

Start
2008-02
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quetiapine Small molecule 200 mg Oral

Indications